8-K 1 b70151rxe8vk.htm RXI PHARMACEUTICALS CORPORATION e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 15, 2008
RXI PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
         
Delaware   001-33958   20-8099512
         
(State or other jurisdiction of
of incorporation or organization) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
60 Prescott Street, Worcester, MA 01605
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 767-3861
          Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
  o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition
Item 9.01 Financial Statements and Exhibits
Signature
Index to Exhibits
EX-99.1 Press release issued by RXi Pharmaceuticals Corporation on May 15, 2008

Table of Contents

Item 2.02 Results of Operations and Financial Condition.
On May 15, 2008, RXi Pharmaceuticals Corporation issued a press release relating to its results of operations and financial conditions for the quarter ended March 31, 2008. A copy of the press release is furnished as Exhibit 99.1 to this form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits  
99.1   Press Release issued by RXi Pharmaceuticals Corporation on May 15, 2008.

 

Table of Contents

Signature
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
             
 
           
    RXI PHARMACEUTICALS CORPORATION    
 
            
Date: May 20, 2008
  By:   /s/ Stephen J. DiPalma     
 
           
 
  Name:   Stephen J. DiPalma    
 
  Title:   Chief Financial Officer    

 

Table of Contents

Index to Exhibits
     
Exhibit No.   Description
99.1
  Press Release issued by RXi Pharmaceuticals Corporation on May 15, 2008.